Aortic DissectionNCT04907071
Intravascular Ultrasound for the Evaluation of Malperfusion Syndrome in the Setting of Acute Aortic Dissection
A study testing Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) in people with Aortic Dissection and Perfusion; Complications, run by London Health Sciences Centre at 1 site in Canada.
Trial summary
Aortic dissection is a life-threatening condition caused by a tear in the internal layer of major artery wall (aorta) that carries blood to all body organs, resulting in separation of the aortic wall layers (dissection). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Aortic Dissection, Perfusion; Complications
- What is being tested?
- Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteCanada
- Study dates
- 1 Mar 2022to 30 Dec 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients diagnosed with an AAD or acute on chronic aortic dissection, with a new diagnosis of malperfusion syndrome (Malperfusion Primary Cohort), by meeting both of the following criteria:
- Imaging findings indicating reduced flow to the Celiac Trunk, Superior mesenteric artery, either renal artery or either iliac artery
- Clinical stigmata of end organ ischemia (abdominal pain, distended abdomen, oliguria/anuria, reduced pulses, signs of limb ischemia) correlating with imaging findings
- OR
- o Laboratory findings suggestive of end organ ischemia (lactic acidosis, elevated LFTs, Elevated Creatinine, Rhabdomyolysis, Electrolyte abnormalities) correlating with imaging findings
- Patients diagnosed with an AAD undergoing surgical repair without evidence of malperfusion syndrome preoperatively, but who develop malperfusion syndrome due to dynamic flow changes after true lumen flow is reinstituted intraoperatively as indicated by new clinical signs or new laboratory results meeting the following criteria (Malperfusion Secondary Cohort):
Show all 9Show fewer
- New Clinical signs include: Loss of femoral pulses, distended abdomen, reduced urine output, dusky/cold extremities
- New Laboratory results include: Rising lactate (>50% above baseline), Rising Creatinine, Metabolic Acidosis, Rising LFTs
- Patients diagnosed with an AAD undergoing surgical repair without evidence of malperfusion syndrome preoperatively and postoperatively (No Malperfusion Cohort).
Who cannot join
- Subject has not been diagnosed with AAD, or acute on chronic aortic dissection
- Subject is not hemodynamically stable to undergo IVUS evaluation
- Subject has anatomy or pre-existing condition precluding safe use of IVUS evaluation
- Subject has a pre-existing condition that may explain evidence of malperfusion (i.e. Dialysis patient with severe renal stenosis).
- Subject or substitute decision maker has language barrier and no translator available at the time of obtaining informed consent to participate in the study.
Trial locations and contacts
1 site in 1 country.
Canada1 site
London Health Scince Center - University Hospital
London, Ontario, N5X0M5
About this study
Official title: Intravascular Ultrasound for the Evaluation of Malperfusion Syndrome in the Setting of Acute Aortic Dissection: A Pilot Study.
Aortic dissection is a life-threatening condition caused by a tear in the internal layer of major artery wall (aorta) that carries blood to all body organs, resulting in separation of the aortic wall layers (dissection). The dissected aorta compromises blood flow to any organ, and eventually leads to organ damage (Malperfusion Syndrome).
Our goal in this project is to use Intravascular Ultrasound (IVUS) to have real time assessment and confirm any evidence of malperfusion syndrome in the setting of aortic dissection after repairing the original aortic tear. IVUS is a small ultrasound (sound waves) wand that is attached to the top of a thin tube. This tube is inserted into the aorta from the groin. This device takes pictures of the aorta and its major branches, to identify problems with blood flow. Having this real-time and dynamic assessment will help to identify any malperfused organs before leaving the operating room and allow us to address the malperfusion syndrome as quickly as possible to limit complications. Without this technique, identifying the problem can take several days after surgery at which point there can be irreversible complications.
Read the detailed description
Acute Type A Aortic Dissection
A Debakey acute type A aortic dissection (ATAAD) represents a lethal condition with a risk of mortality of 1% per hour and up to nearly 50% in first 48 hours if left untreated.1, 2 Traditional surgical teaching has always involved emergent repair of the proximal aortic with resection and replacement of the intima entry tear and aneurysmal tissue within the ascending aorta. This approach addresses obviates the risk of aortic rupture, proximal extension into the coronary arteries, cardiac tamponade and aortic valve insufficiency, all of which lead to mortality. However, as expertise in the field progress evidence is emerging that dealing with only the proximal extent of the dissection may still leave a significant portion of patients at risk for complications from an inability to identify and treat end-organ malperfusion.3 At Western University and London Health Sciences center our mortality rate for patients presenting the ATAAD has been reporter at 20.0%4, and is similar to that reported by the International Registry of Acute aortic Dissection (IRAD) database, with mortality rates between 16.2 and 27.4%.5,6
Malperfusion Syndrome and Aortic Rupture In the 2018 Circulation paper published by Yang et al. the University of Michigan group outline the treatment strategy for ATAAD.
In this study, all patients with an ATAAD presenting with malperfusion, but without signs of aortic rupture or cardiac tamponade, were treated first with endovascular revascularization followed by delayed open aortic repair.3 The authors report that in the second decade of their experience with this treatment model, the overall mortality dropped to 10.7%.3 When compared to our local data and that published by the IRAD group, it would appear that there are significant improvements that can be made for the treatment of these individuals. The authors report that roughly 1/3 of all patients presented with some form of malperfusion syndrome and that in this group, 87% of the deaths were attributed to organ failure from malperfusion even after fenestration and stenting. Conversely there was only a 4% risk of aortic rupture following fenestration and stenting prior to open surgical repair in this group.3 This would indicate that malperfusion is a significant cause of morbidity and mortality in these patients maybe even more so than the risk of aortic rupture in selective patients but in order to improve our outcomes, we need a better way to assess static and dynamic changes that cause malperfusion as early as possible.
Static and Dynamic Arterial Malperfusion
The concept of static and dynamic obstructions in regards to aortic blood flow, indicates the phenomenon where disruption of laminar flow due to interruption of the intimal layer in and aortic dissection, results in gradients between the true and false lumen which can shear a dissection flap over a branching vessel causing collapse of the true lumen (dynamic), or the development of thrombus within the false lumen resulting in obstruction of a branch vessel (static). Most emergent AAD repairs will involve a baseline CT scan of the chest, abdomen and pelvis, which may identify malperfusion of distal arteries shown by a lack of contrast opacification. However, this is done prior to surgical repair and not an accurate representation of perfusion after proximal surgical repair is completed. Frist of all, at the time of the initial CT scan the intimal tear is still present and flow may not be directed into the true lumen, patients blood pressures may not be controlled which can cause dynamic shifts in the intimal flap favouring either true or false lumen flow, and lastly multiple distal re-entry tears can form throughout the remaining aorta after surgical repair which also have the capability of altering arterial flow. Transesophageal echocardiogram is usually present at the time of open surgical repair, but it is limited to the ascending, arch and descending thoracic aorta and provides little information regarding flow to the visceral segments, kidneys and legs.
Intravascular Ultrasound (IVUS)
Intravascular Ultrasound (IVUS) has been used over the past several decades for the real-time assessment of vascular anatomy in a variety of clinical settings.7 Standard IVUS catheters typically use a 9-French delivery sheath and are run over a 0.035-inch guidewire. The device transducer emits and receives signals at varying frequencies to produce a 360̊ axial image. As surgeons are becoming more familiar with this technology and developing the skill set necessary to use the equipment, including the real-time acquisition and interpretation of images, it permits the full evaluation of the thoracoabdominal aorta including size, tortuosity, and calcification. In the setting of an AAD, IVUS can provide real-time data under physiologic conditions following open proximal repair to indicate the presence of distal re-entry tears, compression of the true lumen and malperfusion to aortic branches. It also, can be used intraoperatively to confirm resolution of malperfusion to the visceral segments and legs after proximal flow is reinsituted into the true lumen.
Study Rationale
As noted above, AAD is a lethal condition that every cardiovascular surgeon is faced with at some point in their career. Although the outcomes at LHSC have been historically very good and are on par with or better than the existing IRAD data, looking at other institutions who have more advanced approaches, there appears to be some room to improve our outcomes even further. We believe that emergent repair of the proximal extent of the AAD, which is the current standard at LHSC, results in stabilization of the aortic valve, protects coronary flow, relieves cardiac tamponade and reduces the risk of aortic rupture. However, this approach leaves patients at risk for distal malperfusion due to distal re-entry tears, patent false lumens and thrombus formation, creating both dynamic and static obstruction. Intraoperative IVUS evaluation would therefore allow for the assessment of distal perfusion immediately following proximal repair in order to identify malperfusion and adjust treatment accordingly to prevent damage from prolonged end-organ ischemia. The purpose of this study is to test the safety and efficacy of intraoperative IVUS immediately following open surgical repair.
Device Description
The study devices are intended to improve outcomes for patients presenting with malperfusion syndrome in the setting of ATAAD. Every subject in the cohort must be deemed treatable with an 8Fr IVUS from an anatomy and clinical safety perspective.
Intravascular ultrasound 0.035 PV catheter system
The investigational 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) is an over the wire catheter-based ultrasound with an 8.2-French profile at the transducer end and 7.0-French shaft diameter. This is run through a 9-French place under surface ultrasound guidance in the common femoral artery. The working length of this catheter is 90 cm, with the ability to imaging a diameter up to 60 mm.7
- Conditions
- Aortic Dissection, Perfusion; Complications
- Being tested
- Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA)
- Keywords
- Malperfusion, Syndrome
- Medical subject headings
- Aortic Dissection, Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA)Device
The investigational 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) is an over the wire catheter-based ultrasound with an 8.2-French profile at the transducer end and 7.0-French shaft diameter. This is run through a 9-French place under surface ultrasound guidance in the common femoral artery. The working length of this catheter is 90 cm, with the ability to imaging a diameter up to 60 mm.7
| Study group | Role | What they receive |
|---|---|---|
| Malperfusion Primary Cohort | Experimental | Patients presenting to hospital with AAD meeting criteria for malperfusion syndrome preoperatively which includes both components:
* Imaging findings indicating reduced flow to the Celiac Trunk, Superior mesenteric artery, either renal artery or either iliac artery
* Clinical stigmata of end organ ischemia (abdominal pain, distended abdomen, oliguria/anuria, reduced pulses, signs of limb ischemia) OR Laboratory findings suggestive of end organ ischemia (lactic acidosis, elevated LFTs, Elevated Creatinine, Rhabdomyolysis, Electrolyte abnormalities) Receives: Device: Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) |
| Malperfusion Secondary Cohort: | Experimental | Patients who develop new clinical signs or laboratory results indicating distal malperfusion after proximal repair of the AAD is complete and proximal blood flow is redirected into the true lumen.
* New Clinical signs include: Loss of femoral pulses, distended abdomen, reduced urine output, dusky extremities
* New Laboratory signs include: Rising lactate (>50% above baseline), Rising Creatinine, Metabolic Acidosis, Rising LFTs Receives: Device: Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) |
| No Malperfusion Cohort | Experimental | Patients presenting with AAD with no evidence of malperfusion syndrome preoperatively and postoperatively. Receives: Device: Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary Safety Endpoint
Composite of all-cause in hospital mortality, acute kidney injury requiring new dialysis, mesenteric ischemia requiring intervention and major vascular complications.
Measured: 30 days
Primary Effectiveness Endpoint
Composite of all-cause in hospital mortality, acute kidney injury requiring dialysis, mesenteric ischemia requiring surgical resection and major vascular complications.
Measured: 30 days
Secondary outcomes (1)
Secondary Effectiveness Endpoint
Composite of length of ICU stay and length of hospitalization.
Measured: 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 May 2021
- Study start1 Mar 2022
- Primary completion30 Dec 2025
- Study completion30 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Aortic DissectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- London Health Sciences Centre
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Karama Bayamin, London Health Sciences Centre
- Investigators
- Mathew Valdis, MD, FRCSC, Study director, London Health Sciences Center , London, Ontario, Canada
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04907071
- Sponsor's protocol ID
- AAD IVUS
- Status last verified
- Apr 2026
- First submitted
- 25 May 2021
- Last updated
- 15 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Tsai T, Nienaber CA, Isselbacher EM, Trimarchi S, Bossone E, Evangelista A, Oh JK, O'Gara P, Suzuki T, Hutchison S, Cooper JV, Meinhardt G, Myrmel T, Eagle KA, Froehlich J. Acute type A aortic dissection: does a primary tear in the aortic arch affect management and outcomes? Insights from the International Registry of Acute Aortic Dissection (IRAD). Circulation 2006; 114:432.8.
HIRST AE Jr, JOHNS VJ Jr, KIME SW Jr. Dissecting aneurysm of the aorta: a review of 505 cases. Medicine (Baltimore). 1958 Sep;37(3):217-79. doi: 10.1097/00005792-195809000-00003. No abstract available.
PubMed 13577293Collins JS, Evangelista A, Nienaber CA, Bossone E, Fang J, Cooper JV, Smith DE, O'Gara PT, Myrmel T, Gilon D, Isselbacher EM, Penn M, Pape LA, Eagle KA, Mehta RH; International Registry of Acute Aortic Dissection (IRAD). Differences in clinical presentation, management, and outcomes of acute type a aortic dissection in patients with and without previous cardiac surgery. Circulation. 2004 Sep 14;110(11 Suppl 1):II237-42. doi: 10.1161/01.CIR.0000138219.67028.2a.
PubMed 15364869Yang B, Rosati CM, Norton EL, Kim KM, Khaja MS, Dasika N, Wu X, Hornsby WE, Patel HJ, Deeb GM, Williams DM. Endovascular Fenestration/Stenting First Followed by Delayed Open Aortic Repair for Acute Type A Aortic Dissection With Malperfusion Syndrome. Circulation. 2018 Nov 6;138(19):2091-2103. doi: 10.1161/CIRCULATIONAHA.118.036328.
PubMed 30474418Valdis M, Adams C, Chu MWA, Kiaii B, Guo L. Comparison of outcomes of root replacement procedures and supracoronary techniques for surgical repair of acute aortic dissection. Can J Surg. 2017 Jun;60(3):198-204. doi: 10.1503/cjs.009116.
PubMed 28570214Hagan PG, Nienaber CA, Isselbacher EM, Bruckman D, Karavite DJ, Russman PL, Evangelista A, Fattori R, Suzuki T, Oh JK, Moore AG, Malouf JF, Pape LA, Gaca C, Sechtem U, Lenferink S, Deutsch HJ, Diedrichs H, Marcos y Robles J, Llovet A, Gilon D, Das SK, Armstrong WF, Deeb GM, Eagle KA. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA. 2000 Feb 16;283(7):897-903. doi: 10.1001/jama.283.7.897.
PubMed 10685714Kpodonu J, Ramaiah VG, Diethrich EB. Intravascular ultrasound imaging as applied to the aorta: a new tool for the cardiovascular surgeon. Ann Thorac Surg. 2008 Oct;86(4):1391-8. doi: 10.1016/j.athoracsur.2008.06.057.
PubMed 18805213
Study at a glance
From the registry record, last updated by the sponsor on 15 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intravascular Ultrasound for the Evaluation of Malperfusion Syndrome in the Setting of Acute Aortic Dissection: A Pilot Study.
- ClinicalTrials.gov ID
- NCT04907071
- Acronym / sponsor ID
- AAD IVUS
- Conditions
- Aortic Dissection, Perfusion; Complications
- Keywords
- Malperfusion, Syndrome
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- London Health Sciences CentreUniversity, hospital or other
- Study start
- 1 Mar 2022 (actual)
- Primary completion
- 30 Dec 2025 (actual)
- Study completion
- 30 Dec 2025 (actual)
- First posted
- 28 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aortic dissection is a life-threatening condition caused by a tear in the internal layer of major artery wall (aorta) that carries blood to all body organs, resulting in separation of the aortic wall layers (dissection). The dissected aorta compromises blood flow to any organ, and eventually leads to organ damage (Malperfusion Syndrome).
Our goal in this project is to use Intravascular Ultrasound (IVUS) to have real time assessment and confirm any evidence of malperfusion syndrome in the setting of aortic dissection after repairing the original aortic tear. IVUS is a small ultrasound (sound waves) wand that is attached to the top of a thin tube. This tube is inserted into the aorta from the groin. This device takes pictures of the aorta and its major branches, to identify problems with blood flow. Having this real-time and dynamic assessment will help to identify any malperfused organs before leaving the operating room and allow us to address the malperfusion syndrome as quickly as possible to limit complications. Without this technique, identifying the problem can take several days after surgery at which point there can be irreversible complications.
Detailed description
Acute Type A Aortic Dissection
A Debakey acute type A aortic dissection (ATAAD) represents a lethal condition with a risk of mortality of 1% per hour and up to nearly 50% in first 48 hours if left untreated.1, 2 Traditional surgical teaching has always involved emergent repair of the proximal aortic with resection and replacement of the intima entry tear and aneurysmal tissue within the ascending aorta. This approach addresses obviates the risk of aortic rupture, proximal extension into the coronary arteries, cardiac tamponade and aortic valve insufficiency, all of which lead to mortality. However, as expertise in the field progress evidence is emerging that dealing with only the proximal extent of the dissection may still leave a significant portion of patients at risk for complications from an inability to identify and treat end-organ malperfusion.3 At Western University and London Health Sciences center our mortality rate for patients presenting the ATAAD has been reporter at 20.0%4, and is similar to that reported by the International Registry of Acute aortic Dissection (IRAD) database, with mortality rates between 16.2 and 27.4%.5,6
Malperfusion Syndrome and Aortic Rupture In the 2018 Circulation paper published by Yang et al. the University of Michigan group outline the treatment strategy for ATAAD.
In this study, all patients with an ATAAD presenting with malperfusion, but without signs of aortic rupture or cardiac tamponade, were treated first with endovascular revascularization followed by delayed open aortic repair.3 The authors report that in the second decade of their experience with this treatment model, the overall mortality dropped to 10.7%.3 When compared to our local data and that published by the IRAD group, it would appear that there are significant improvements that can be made for the treatment of these individuals. The authors report that roughly 1/3 of all patients presented with some form of malperfusion syndrome and that in this group, 87% of the deaths were attributed to organ failure from malperfusion even after fenestration and stenting. Conversely there was only a 4% risk of aortic rupture following fenestration and stenting prior to open surgical repair in this group.3 This would indicate that malperfusion is a significant cause of morbidity and mortality in these patients maybe even more so than the risk of aortic rupture in selective patients but in order to improve our outcomes, we need a better way to assess static and dynamic changes that cause malperfusion as early as possible.
Static and Dynamic Arterial Malperfusion
The concept of static and dynamic obstructions in regards to aortic blood flow, indicates the phenomenon where disruption of laminar flow due to interruption of the intimal layer in and aortic dissection, results in gradients between the true and false lumen which can shear a dissection flap over a branching vessel causing collapse of the true lumen (dynamic), or the development of thrombus within the false lumen resulting in obstruction of a branch vessel (static). Most emergent AAD repairs will involve a baseline CT scan of the chest, abdomen and pelvis, which may identify malperfusion of distal arteries shown by a lack of contrast opacification. However, this is done prior to surgical repair and not an accurate representation of perfusion after proximal surgical repair is completed. Frist of all, at the time of the initial CT scan the intimal tear is still present and flow may not be directed into the true lumen, patients blood pressures may not be controlled which can cause dynamic shifts in the intimal flap favouring either true or false lumen flow, and lastly multiple distal re-entry tears can form throughout the remaining aorta after surgical repair which also have the capability of altering arterial flow. Transesophageal echocardiogram is usually present at the time of open surgical repair, but it is limited to the ascending, arch and descending thoracic aorta and provides little information regarding flow to the visceral segments, kidneys and legs.
Intravascular Ultrasound (IVUS)
Intravascular Ultrasound (IVUS) has been used over the past several decades for the real-time assessment of vascular anatomy in a variety of clinical settings.7 Standard IVUS catheters typically use a 9-French delivery sheath and are run over a 0.035-inch guidewire. The device transducer emits and receives signals at varying frequencies to produce a 360̊ axial image. As surgeons are becoming more familiar with this technology and developing the skill set necessary to use the equipment, including the real-time acquisition and interpretation of images, it permits the full evaluation of the thoracoabdominal aorta including size, tortuosity, and calcification. In the setting of an AAD, IVUS can provide real-time data under physiologic conditions following open proximal repair to indicate the presence of distal re-entry tears, compression of the true lumen and malperfusion to aortic branches. It also, can be used intraoperatively to confirm resolution of malperfusion to the visceral segments and legs after proximal flow is reinsituted into the true lumen.
Study Rationale
As noted above, AAD is a lethal condition that every cardiovascular surgeon is faced with at some point in their career. Although the outcomes at LHSC have been historically very good and are on par with or better than the existing IRAD data, looking at other institutions who have more advanced approaches, there appears to be some room to improve our outcomes even further. We believe that emergent repair of the proximal extent of the AAD, which is the current standard at LHSC, results in stabilization of the aortic valve, protects coronary flow, relieves cardiac tamponade and reduces the risk of aortic rupture. However, this approach leaves patients at risk for distal malperfusion due to distal re-entry tears, patent false lumens and thrombus formation, creating both dynamic and static obstruction. Intraoperative IVUS evaluation would therefore allow for the assessment of distal perfusion immediately following proximal repair in order to identify malperfusion and adjust treatment accordingly to prevent damage from prolonged end-organ ischemia. The purpose of this study is to test the safety and efficacy of intraoperative IVUS immediately following open surgical repair.
Device Description
The study devices are intended to improve outcomes for patients presenting with malperfusion syndrome in the setting of ATAAD. Every subject in the cohort must be deemed treatable with an 8Fr IVUS from an anatomy and clinical safety perspective.
Intravascular ultrasound 0.035 PV catheter system
The investigational 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) is an over the wire catheter-based ultrasound with an 8.2-French profile at the transducer end and 7.0-French shaft diameter. This is run through a 9-French place under surface ultrasound guidance in the common femoral artery. The working length of this catheter is 90 cm, with the ability to imaging a diameter up to 60 mm.7
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Malperfusion Primary Cohort | Experimental | Device: Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA)Patients presenting to hospital with AAD meeting criteria for malperfusion syndrome preoperatively which includes both components: * Imaging findings indicating reduced flow to the Celiac Trunk, Superior mesenteric artery, either renal artery or either iliac artery * Clinical stigmata of end organ ischemia (abdominal pain, distended abdomen, oliguria/anuria, reduced pulses, signs of limb ischemia) OR Laboratory findings suggestive of end organ ischemia (lactic acidosis, elevated LFTs, Elevated Creatinine, Rhabdomyolysis, Electrolyte abnormalities) |
| Malperfusion Secondary Cohort: | Experimental | Device: Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA)Patients who develop new clinical signs or laboratory results indicating distal malperfusion after proximal repair of the AAD is complete and proximal blood flow is redirected into the true lumen. * New Clinical signs include: Loss of femoral pulses, distended abdomen, reduced urine output, dusky extremities * New Laboratory signs include: Rising lactate (>50% above baseline), Rising Creatinine, Metabolic Acidosis, Rising LFTs |
| No Malperfusion Cohort | Experimental | Device: Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA)Patients presenting with AAD with no evidence of malperfusion syndrome preoperatively and postoperatively. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (9 listed)
- Patients diagnosed with an AAD or acute on chronic aortic dissection, with a new diagnosis of malperfusion syndrome (Malperfusion Primary Cohort), by meeting both of the following criteria:
- OR
- o Laboratory findings suggestive of end organ ischemia (lactic acidosis, elevated LFTs, Elevated Creatinine, Rhabdomyolysis, Electrolyte abnormalities) correlating with imaging findings
- Patients diagnosed with an AAD undergoing surgical repair without evidence of malperfusion syndrome preoperatively, but who develop malperfusion syndrome due to dynamic flow changes after true lumen flow is reinstituted intraoperatively as indicated by new clinical signs or new laboratory results meeting the following criteria (Malperfusion Secondary Cohort):
- Patients diagnosed with an AAD undergoing surgical repair without evidence of malperfusion syndrome preoperatively and postoperatively (No Malperfusion Cohort).
Key exclusion criteria (5 listed)
- Subject has not been diagnosed with AAD, or acute on chronic aortic dissection
- Subject is not hemodynamically stable to undergo IVUS evaluation
- Subject has anatomy or pre-existing condition precluding safe use of IVUS evaluation
- Subject has a pre-existing condition that may explain evidence of malperfusion (i.e. Dialysis patient with severe renal stenosis).
- Subject or substitute decision maker has language barrier and no translator available at the time of obtaining informed consent to participate in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA)The investigational 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) is an over the wire catheter-based ultrasound with an 8.2-French profile at the transducer end and 7.0-French shaft diameter. This is run through a 9-French place under surface ultrasound guidance in the common femoral artery. The working length of this catheter is 90 cm, with the ability to imaging a diameter up to 60 mm.7 | Device | Malperfusion Primary Cohort, Malperfusion Secondary Cohort:, No Malperfusion Cohort |
Primary outcome
Primary Safety Endpoint
Time frame: 30 days
Composite of all-cause in hospital mortality, acute kidney injury requiring new dialysis, mesenteric ischemia requiring intervention and major vascular complications.
Primary Effectiveness Endpoint
Time frame: 30 days
Composite of all-cause in hospital mortality, acute kidney injury requiring dialysis, mesenteric ischemia requiring surgical resection and major vascular complications.
1 secondary outcome
Secondary Effectiveness Endpoint
Time frame: 30 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Apr 2026.
- BackgroundTsai T, Nienaber CA, Isselbacher EM, Trimarchi S, Bossone E, Evangelista A, Oh JK, O'Gara P, Suzuki T, Hutchison S, Cooper JV, Meinhardt G, Myrmel T, Eagle KA, Froehlich J. Acute type A aortic dissection: does a primary tear in the aortic arch affect management and outcomes? Insights from the International Registry of Acute Aortic Dissection (IRAD). Circulation 2006; 114:432.8.
- Results publication: PubMed 13577293HIRST AE Jr, JOHNS VJ Jr, KIME SW Jr. Dissecting aneurysm of the aorta: a review of 505 cases. Medicine (Baltimore). 1958 Sep;37(3):217-79. doi: 10.1097/00005792-195809000-00003. No abstract available.
- Results publication: PubMed 15364869Collins JS, Evangelista A, Nienaber CA, Bossone E, Fang J, Cooper JV, Smith DE, O'Gara PT, Myrmel T, Gilon D, Isselbacher EM, Penn M, Pape LA, Eagle KA, Mehta RH; International Registry of Acute Aortic Dissection (IRAD). Differences in clinical presentation, management, and outcomes of acute type a aortic dissection in patients with and without previous cardiac surgery. Circulation. 2004 Sep 14;110(11 Suppl 1):II237-42. doi: 10.1161/01.CIR.0000138219.67028.2a.
- Results publication: PubMed 30474418Yang B, Rosati CM, Norton EL, Kim KM, Khaja MS, Dasika N, Wu X, Hornsby WE, Patel HJ, Deeb GM, Williams DM. Endovascular Fenestration/Stenting First Followed by Delayed Open Aortic Repair for Acute Type A Aortic Dissection With Malperfusion Syndrome. Circulation. 2018 Nov 6;138(19):2091-2103. doi: 10.1161/CIRCULATIONAHA.118.036328.
- Results publication: PubMed 28570214Valdis M, Adams C, Chu MWA, Kiaii B, Guo L. Comparison of outcomes of root replacement procedures and supracoronary techniques for surgical repair of acute aortic dissection. Can J Surg. 2017 Jun;60(3):198-204. doi: 10.1503/cjs.009116.
- Results publication: PubMed 10685714Hagan PG, Nienaber CA, Isselbacher EM, Bruckman D, Karavite DJ, Russman PL, Evangelista A, Fattori R, Suzuki T, Oh JK, Moore AG, Malouf JF, Pape LA, Gaca C, Sechtem U, Lenferink S, Deutsch HJ, Diedrichs H, Marcos y Robles J, Llovet A, Gilon D, Das SK, Armstrong WF, Deeb GM, Eagle KA. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA. 2000 Feb 16;283(7):897-903. doi: 10.1001/jama.283.7.897.
- Results publication: PubMed 18805213Kpodonu J, Ramaiah VG, Diethrich EB. Intravascular ultrasound imaging as applied to the aorta: a new tool for the cardiovascular surgeon. Ann Thorac Surg. 2008 Oct;86(4):1391-8. doi: 10.1016/j.athoracsur.2008.06.057.
- Individual participant dataSharing planned: No
Related trials for Aortic Dissection
Not yet recruitingPhase 2
D2 Gastrectomy With or Without Para-Aortic Lymph Node Dissection After Chemoimmunotherapy for Gastric Cancer
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Not yet recruitingObservational study
Clinical Health Outcomes Evaluation of Terumo Aortic Hybrid Devices
Aortic Aneurysm and Dissection
Recruiting
GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study
Aortic Arch Dissection, Aortic Arch Aneurysm
RecruitingObservational study
Metabolic Phenotyping in vEDS
Vascular Ehlers-Danlos Syndrome, Vascular Ehlers Danlos Syndrome
Not yet recruitingObservational study
Real-World Data Collection of GORE Devices Used In the Endovascular Treatment of Aortic Aneurysms Which Incorporate Visceral Arteries.
Complex Aortic Aneurysms, Thoracoabdominal Aneurysm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mathew Valdis, MD, FRCSC study director
London Health Sciences Center , London, Ontario, Canada
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Intravascular ultrasound 0.035 PV IVUS catheter (Volcano Therapeutics, Rancho Cordova, CA) in people with Aortic Dissection and Perfusion; Complications, run by London Health Sciences Centre at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary Safety Endpoint (time frame: 30 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04907071, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2026.